Fucoidan-Doxorubicin Nanoparticles Targeting P-Selectin for Effective Breast Cancer Therapy.

Area of Science:

• Biomaterials Science
• Cancer Biology
• Drug Delivery Systems

Background:

• Fucoidan, a sulfated polysaccharide, exhibits anticoagulant, anti-tumor, and anti-inflammatory properties.
• P-selectin is crucial in cancer metastasis, promoting cancer cell adhesion and is overexpressed in various cancer types.
• Doxorubicin (Dox) is a potent chemotherapy drug with significant side effects.

Purpose of the Study:

• To synthesize a fucoidan-based drug delivery system for targeted delivery of doxorubicin (Dox).
• To minimize doxorubicin's side effects through active targeting of P-selectin.
• To evaluate the efficacy of the developed nanoparticles in vitro.

Main Methods:

• Direct conjugation of doxorubicin (Dox) to the fucoidan backbone to create fucoidan-doxorubicin nanoparticles (FU-Dox NPs).
• Characterization of nanoparticle size distribution and drug release kinetics.
• Assessment of cellular uptake and cytotoxicity in cancer cell lines with varying P-selectin expression.

Main Results:

• FU-Dox NPs demonstrated controlled size distribution and sustained drug release.
• Targeting P-selectin led to enhanced cellular uptake of FU-Dox NPs in MDA-MB-231 cells (high P-selectin expression).
• Increased cytotoxicity was observed in MDA-MB-231 cells compared to MDA-MB-468 cells (low P-selectin expression).

Conclusions:

• Fucoidan-based nanoparticles offer a promising platform for targeted doxorubicin delivery.
• Active targeting of P-selectin enhances the efficacy of chemotherapy by improving cellular uptake and cytotoxicity.
• This approach holds potential for reducing chemotherapy side effects and improving cancer treatment outcomes.